I would say that the efficient system for generic competition is an important basis. It creates headroom for innovation, and that leaves us in a good place when it comes to our relatively high, I would say, willingness to pay for new pharmaceuticals that bring added value. Having the value-based approach and trying to develop our decisions on our follow-ups in such a way as to pay for performance or pay for results and link that to our developed real world data work has also, I think, helped.
Also, as my colleague said, it's the combination of both, and it's also due to our collaborative framework for dialogues with the county councils and the pharma companies.